As the pharmaceutical industry accelerates toward greener operations, primary packaging—especially blister packs—has come under increasing scrutiny. Two dominant formats, thermoform and cold-form (Alu–Alu) blisters, are now at the center of a critical sustainability debate: how do we balance environmental responsibility with drug protection?
The Sustainability Trade-Off
Thermoform blisters, typically made from materials like Polyvinyl Chloride (PVC), Polypropylene (PP), or Polyethylene Terephthalate (PET), are widely regarded as the more sustainable option from a packaging perspective. They use thinner films, require less material, and benefit from energy-efficient, high-speed manufacturing processes. Their lightweight nature also reduces transport-related emissions.
However, sustainability challenges remain. Multi-layer structures—often incorporating coatings such as Polyvinylidene Chloride (PVDC)—can make recycling difficult, and PVC-based formats continue to raise environmental concerns.
In contrast, cold-form blisters, made from laminated layers including aluminum, provide near-perfect protection against moisture, oxygen, and light. This makes them essential for highly sensitive or high-value drugs. But this performance comes at a cost: aluminum production is energy-intensive, and the resulting multi-layer laminates are difficult to recycle, contributing to a higher overall carbon footprint.
Protection vs Environmental Impact
The core dilemma is clear:
- Thermoform blisters offer better material efficiency and are evolving toward recyclable, mono-material designs.
- Cold-form blisters ensure maximum product stability and extended shelf life, significantly reducing the risk of drug waste.
This trade-off is particularly important when considering that pharmaceutical products themselves carry a substantial environmental footprint. In many cases, preventing drug degradation may outweigh the environmental cost of more resource-intensive packaging.
Innovation Driving Change
Encouragingly, the industry is actively working to close this gap. Key developments include:
- Transition to PVC-free, mono-material thermoform films
- Adoption of advanced polymers such as Cyclic Olefin Copolymer (COC) for improved barrier performance
- Introduction of ultra-thin barrier coatings that maintain recyclability
- Exploration of hybrid solutions combining high-barrier performance with reduced material use
These innovations aim to deliver the best of both worlds: robust drug protection with a lower environmental impact.
The Road Ahead
There is no one-size-fits-all solution. The most sustainable choice depends on the specific drug, its sensitivity, and its distribution requirements. For less sensitive products, thermoform solutions—especially next-generation recyclable designs—are increasingly preferred. For highly sensitive or high-value medications, cold-form packaging remains indispensable.
Ultimately, the future of pharmaceutical packaging lies in holistic lifecycle thinking, where both packaging materials and product integrity are considered together.
At Kerimed, we continue to monitor these developments closely, supporting solutions that align performance, compliance, and sustainability in an evolving pharmaceutical landscape.